Drug Profile


Alternative Names: INCB-039110; INCB39110

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Non-small cell lung cancer
  • Phase I/II Hodgkin's disease; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
  • Discontinued Myelofibrosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 05 Dec 2016 Incyte Corporation terminates a phase-II clinical trial in Non-small cell lung cancer (Combination therapy) in USA (PO) (NCT02257619)
  • 01 Nov 2016 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT02917993)
  • 23 Sep 2016 Incyte plans a phase II trial for Chronic Idiopathic Pruritus in USA (NCT02909569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top